&w=3840&q=100)
Aurobindo Pharma to manufacture, supply long acting HIV treatment drug
Press Trust of India
Aurobindo Pharma on Tuesday said it will manufacture and supply the long-acting injectable HIV treatment cabotegravir across 133 countries.
The Hyderabad-based drugmaker has been selected as one of the generic manufacturers under the expanded voluntary licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare, the company said in a statement.
The agreement allows Aurobindo to manufacture and supply the long-acting injectable HIV treatment across 133 countries, including several low and middle-income markets, it added.
This update now includes long-acting cabotegravir (CAB LA) for HIV treatment, in addition to its earlier use for prevention only.
The treatment offers an alternative to daily pills, allowing patients to receive just one injection every one or two months.
"We are privileged to be part of the sub-license expansion from MPP and ViiV to develop, manufacture, and distribute generic CAB LA in select markets for the treatment of HIV-1, in addition to the voluntary licence for PrEP," Aurobindo Pharma Vice Chairman & Managing Director K Nithyananda Reddy said.
This is a significant and timely step towards increasing access to advanced long-acting treatment in LMICs, he added.
Aurobindo remains committed to leveraging its global supply capabilities to make this vital combination long-acting injection therapy widely available and affordable, he stated.
The consideration by ViiV and MPP to include the private market in royalty-bearing countries is a critical step toward expanding access across both public and private sectors, it added.
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, and the Medicines Patent Pool (MPP), have announced an update to their voluntary licensing agreement to include patents relating to its use in a long-acting regimen.
The announcement follows updated guidance from the WHO recommending long-acting injectable cabotegravir + rilpivirine as an HIV treatment option.
Existing generic licensees for prevention will be able to develop, manufacture and supply generic CAB LA, for use in combination with long-acting rilpivirine, subject to required regulatory approvals, to help enable access to the long-acting treatment in 133 countries worldwide.
This includes all least-developed, low-income, lower middle-income, and Sub-Saharan African countries, as well as countries where ViiV does not have patent rights for cabotegravir.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
31 minutes ago
- The Hindu
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug
Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused on HIV medicines and majority owned by GSK with Pfizer and Shionogi as shareholders, and Medicines Patent Pool (MPP) extending their voluntary licensing agreement to enable access to long-acting injectable HIV treatment. It builds on the voluntary license for CAB LA for HIV pre-exposure prophylaxis (PrEP). The announcement, on extending their agreement, comes in the wake of an updated guidance from World Health Organization (WHO) recommending long-acting injectable cabotegravir + rilpivirine as an HIV treatment option. Existing licensees Aurobindo, Cipla and Viatris will consequently be able to develop, manufacture and supply generic versions of CAB LA, for use in combination with long-acting rilpivirine, for the treatment of HIV-1 infection in adults and adolescents weighing at least 35kg subject to required regulatory approvals being obtained, Aurobindo Pharma said on Tuesday. Vice chairman and MD of Aurobindo Pharma K. Nithyananda Reddy said the company remains committed to leveraging its global supply capabilities to make the vital combination long-acting injection therapy widely available and affordable. The consideration by ViiV and MPP to include the private market in royalty-bearing countries is a critical step toward expanding access across both public and private sectors, he said.
First Post
an hour ago
- First Post
How India Stopped a $4.3 Billion Trading Spree Vantage with Palki Sharma
How India Stopped a $4.3 Billion Trading Spree | Jane Street | Vantage with Palki Sharma How India Stopped a $4.3 Billion Trading Spree | Jane Street | Vantage with Palki Sharma India's securities regulator has temporarily barred US-based Jane Street from its markets, accusing the firm of manipulating indices to make $570 million in unlawful gains. SEBI alleges Jane Street used vast funds to distort futures and cash markets, misleading smaller traders while profiting from options trades. The interim order freezes the firm's accounts and demands repayment, while Jane Street disputes the findings. The rare move sends a message to global high-frequency traders about unfair practices. The case highlights growing scrutiny of foreign firms in India's booming derivatives market, which has seen record retail losses alongside surging institutional profits. See More
Time of India
an hour ago
- Time of India
Trump to unveil investments to power AI boom
Academy Empower your mind, elevate your skills US president Donald Trump heads to Pennsylvania on Tuesday to announce energy and infrastructure deals intended to meet big tech's soaring demand for electricity needed to fuel the AI will make the announcement at the inaugural Pennsylvania Energy and Innovation Summit at Carnegie Mellon tech world has fully embraced generative AI as the next wave of technology, but fears are growing that its massive electricity needs cannot be met by current infrastructure, particularly in the United AI requires enormous computing power, mainly to run the energy-hungry processors from Nvidia, the California-based company that has become the world's most valuable company by market expect that by 2028, tech companies will need as much as five gigawatts of power for AI -- enough electricity to power roughly five million to an official who spoke to Bloomberg, Trump's announcement will total $70 billion in executives from BlackRock, Palantir, Anthropic, Exxon and Chevron are slated to participate, the official funding will cover new data centers, power generation, grid infrastructure, AI training, and apprenticeship programs. Google said it is committing $25 billion to build AI-ready data centers in Pennsylvania and surrounding regions."We support President Trump's clear and urgent direction that our nation invest in AI... so that America can continue to lead in AI," said Ruth Porat, Google's president and chief investment officer, who attended the search engine giant also announced a partnership with Brookfield Asset Management to to modernize two hydropower facilities in Pennsylvania, representing 670 MW of capacity on the regional David McCormick, from Pennsylvania, said the investments "are of enormous consequence to Pennsylvania, but they are also crucial to the future of the nation."His comments reflect the growing sentiment in Washington that the United States must not lose ground to China in the race to develop AI."If the United States does not lead this revolution on our own terms, we will hand control of our infrastructure, our data, our leadership, and our way of life to Communist China," McCormick wrote in a Fox News launched the "Stargate" project in January, aimed at investing up to $500 billion in US AI infrastructure -- primarily in response to growing competition with tech investor SoftBank, ChatGPT-maker OpenAI, and Oracle are investing $100 billion in the initial has also reversed many policies adopted by the previous Biden administration that imposed checks on developing powerful AI algorithms and limits on exports of advanced technology to certain allied is expected to outline his own blueprint for AI advancement later this month.
